Microgravity grows better biological tissue than any terrestrial cleanroom, and reaching orbit costs a fortune. Helogen, a New York company founded in 2022, has raised $7.1 million to run both sides of that contradiction at once.
Its HEL-IOS platform flies its first two complete orbital missions in October 2026. Both are rideshares, one brokered with D-Orbit. Both are production runs.
What they carry is the first real test of whether a material made off-planet can support the price of the trip: a bone substitute designed at University College London, and an artificial-retina protein from the biotech firm LambdaVision.
The case for leaving the ground
Gravity is a manufacturing variable, and it is usually a bad one. Inside a bioreactor on Earth, cells settle and clump, distributing unevenly the way blueberries sink through muffin batter. In free fall they hold their position, so printed tissue keeps the architecture it was designed with.
The effect is measurable. Stem cells mature and differentiate faster once gravity stops biasing them. A bone model that loses density in orbit compresses a process that takes roughly three years to observe on the ground into a single 30-day mission.
UCL's BIO-BONE, a 3D-printed hydroxyapatite substitute matched to native bone in porosity and mechanical behaviour, is flying to borrow that acceleration. The sample itself is almost beside the point. What matters is how quickly a disease model can be run, and how many iterations a researcher can get per flight.
Helogen's argument is that the whole factory belongs in orbit, not only the payload. HEL-IOS bundles cell and tissue cultivation, media and fluid handling, environmental control, processing, separation, harvest, and in-process quality monitoring into one closed loop that runs with no continuous crew. A 2025 NASA TechLeap Prize and an integration agreement with Starlab, the commercial station, point at the same idea: give the biology a permanent industrial node instead of a disposable experiment.
That is the technical case, and it is coherent. Sterile, force-free, uninterrupted, and instrumented at every stage.
Consider that last property. A terrestrial process can be sampled mid-run by a technician with a pipette. An orbital one can only be observed through its own sensors until a return vehicle opens on the ground. HEL-IOS carries in-line analytics for exactly that reason, and the telemetry it transmits is a product in its own right — a continuous record of a process that no human supervised.
The case for staying on Earth
The counter-case is arithmetic. Helogen has raised $7.1 million in total. Dealroom places that seed in the top 5% of US nanotech rounds, and it is still a rounding error next to the capital a GMP-certified production line consumes on the ground.
Seed round, September 2026
Co-led by RRE Ventures and Oceans, with One Way Ventures, Blisce, AUM, Aurelia Foundry, and Mana VC. Dealroom, 2026
Launch is a recurring toll. Every kilogram lifted and every sample returned carries a marginal expense a terrestrial bioprocess never sees. The assumption that heavy-lift gets cheap enough to erase that gap rests on a rocket roadmap Helogen does not control.
Then there is the market. The near-term product is a tissue patch. Auxilium Biotechnologies returned bioprinted liver and kidney tissue from the ISS in June, and its chief executive has been explicit that the field will focus on small repair patches long before it prints anything whole. A patch is a real product. It is also a narrow one, sold into a research and regenerative-medicine market that already has working terrestrial suppliers.
The premium has to clear a high bar. A material must be so hard to make on Earth that a hospital, a lab, or a pharma sponsor will accept orbit-inclusive pricing and wait for a return capsule with the result. Very few products clear that test today, and the ones that might — high-value crystallised drugs, specific protein films — are exactly the ones a competitor can later learn to make in a ground lab.
Set the two cases side by side and the disagreement narrows to four constraints.
| Constraint | Terrestrial cleanroom | Low Earth orbit |
|---|---|---|
| Cell behaviour | ✔ Settles and clumps; uneven distribution | ✔ Holds position; even 3D structure |
| Maturation speed | ◐ Baseline timeline | ✔ Faster differentiation |
| Marginal cost | ✔ Established, predictable | ✗ Launch and return per kilogram |
| Regulatory record | ✔ Mature GMP frameworks | ◐ Custody protocols still being defined |
Process comparison, Helogen and industry disclosures, 2026
What the first two missions actually prove
The October flights are a regulatory milestone ahead of a production one. One mission carries the UCL bone model; the other carries LambdaVision's retina protein, which is also that company's first flight outside the ISS. Both are structured as full operational validations: ground preparation, flight qualification, in-orbit manufacture, sample return, and custody transfer.
That chain is the deliverable. GMP compliance is ultimately a paper trail — custody, traceability, handling standards, and validated process control. A mission that returns a manufactured sample with an unbroken chain of custody hands a regulator the first artifact worth inspecting.
The scarce resource in this sector is not free fall and it is not capital. It is a manufacturing record the FDA will accept. Two flights that produce one are worth more to the category than a hundred that produce a headline.
Helogen frames its platform around that discipline.
Every mission on HEL-IOS is built around the operational rigor that regulated manufacturing demands.— Shishir Bankapur, chief executive, Helogen Corporation
The company is not alone in the wager. Axiom Space has said its first commercial station module will berth no earlier than 2028, with microgravity biomanufacturing as a named use case. Payload notes that Helogen has flown subsystems before, but October marks the first time the entire platform leaves the ground as one system. A category is forming around named customers before any of them has shipped at industrial volume.
As we wrote in October, the economics of Varda Space's microgravity-pharma push turned on the same open question — what a product made in orbit is worth once it lands.
Where the premium actually is
If the orbital case survives, it will not survive on cost. It will survive on scarcities that terrestrial manufacturing cannot remove: the absence of settling, the acceleration of slow biological processes, and a level of automation that removes the human contaminant from the loop entirely. Those advantages are real, and they are small in number.
That is what makes the bet legible. Helogen is not selling cheap manufacturing. It is selling a narrow class of materials that only free fall can produce at quality, and a regulatory record that proves it happened. Everything else — the launch cadence, the return logistics, the customer list — is execution that the next round of capital will test.
The near-term product is a tissue patch at a research-market price, not a printed organ.
The durable asset is a GMP-grade chain of custody, and building it takes missions rather than announcements.
The question for 2027 is whether a hospital or a pharma sponsor will pay orbit-inclusive prices for a material that used to be impossible to order at all, and whether the FDA accepts a new kind of manufacturing record. Until both answers land, the October missions are a wager on the paperwork as much as the tissue.